The Globalvirtual biopsy market is expected to grow from USD 0.78 bn in 2025 to reach USD 0.85 bn in 2026 and USD 3.02 bn by 2035, representing a CAGR of 15% during the forecast period.

Virtual biopsy technique have emerged as a critical tool in offering non invasive and accurate diagnostic and screening facilities in healthcare. Owing to these benefits, several companies are working on their proprietary technologies to develop virtual biopsy devices to enhance current patient care management. During our research, we identified over 45 virtual biopsy devices designed by nearly 25 developers, globally. The virtual biopsy market is highly fragmented, featuring the presence of both established companies as well as emerging start-ups. Most (15) of the virtual biopsy device developers were established between 1982-2018. Notably, five players have entered the domain post-2018; these include (in reverse chronological order) HepaVue (2023), KENKO Imalytics (2021), PONS (2021), AI Metrics (2019) and SynDiag (2019).

Majority (~15) of the virtual biopsy devices utilize magnetic resonance imaging technology for image acquisition process, owing to the fact that MRI utilizes non-ionizing radiations which captures three dimensional and high resolution images, covering wider surface area. This is followed by the usage of computed tomography, X-ray and ultrasound technology for data capturing. Notable examples of virtual biopsy devices that employed only MRI include (in alphabetical order, used for image acquisition) dVIEWR powered by MICE Toolkit (Random Walk Imaging), IB NEURO (Imaging Biometrics), QP-Brain (Quibim), QP-Breast (Quibim), QP-Liver (Quibim) and QP-Prostate (Quibim).

That majority (~30) of the virtual biopsy devices are used for diagnostic purposes. By analyzing radiological images through techniques such as radiomics, virtual biopsy can extract quantitative features that correlate with the biological characteristics of tumors. This allows for more precise differentiation between benign and malignant lesions. , Additionally, virtual biopsy device developers designed several devices that can cater for both diagnostic and research requirements. Examples of devices designed for both diagnosis and research purposes include (in alphabetical order, under development) OnX (Oncoustics) and Vibrational Optical Coherence Tomography (VOCT) (OptoVibronex).

During our research, we came across several partnerships and collaborations that have been inked between different stakeholders engaged in the virtual biopsy market.

It is worth mentioning that the number of partnerships inked in this domain has increased over time at a CAGR of 18%, since 2020. most of the deals (30) were instances of technological integration, enabling the players to improve their current virtual biopsy product portfolio. By incorporating advanced technologies, such as artificial intelligence and deep learning, data can be processed and analyzed accurately and at faster rates, significantly improving the efficiency and speed of virtual biopsy offerings.

Read more – https://www.rootsanalysis.com/reports/virtual-biopsy-market.html